![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, May 07, 2024 3:21:24 PM
Its funny how the narrative changes from month to month. It started with "no peer-review", we got that in JAMA. Then it was there would never be a submitted marketing app...we got that. Now we get "they arent running pediatric trials" so it wont be approved. Do you know how absurd this is?
Here is a tidbit for you:
"In the United Kingdom, drug companies typically need to run pediatric trials when seeking approval for a new drug if the medication is intended for use in children or if it could potentially be used in pediatric populations. This requirement stems from the European Pediatric Regulation, which mandates that drug developers conduct studies in children as part of the drug development process.
Specifically, pediatric trials are required when the drug is intended for:
1) Treatment of pediatric diseases or conditions: If the drug is intended to treat diseases or conditions that primarily affect children, pediatric trials are usually necessary to establish safety, efficacy, and appropriate dosing in pediatric populations.
2) Off-label use in children: Even if a drug is primarily developed and approved for use in adults, if it's anticipated that healthcare providers might prescribe it to children (off-label use), pediatric trials may be required to assess safety and effectiveness in that population.
The goal of requiring pediatric trials is to ensure that medications used in children are thoroughly evaluated for safety and efficacy, as children may respond differently to drugs compared to adults. This regulation aims to promote the development of safe and effective medicines for pediatric populations."
The fact is NW doesnt even need to run P trials if they never intent to use it in children, but the market is much larger with children included. Glad they got a approved PIP.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM